TY - JOUR T1 - The excess insulin requirement in severe COVID-19 compared to non-COVID-19 viral pneumonitis is related to the severity of respiratory failure and pre-existing diabetes JF - medRxiv DO - 10.1101/2020.10.03.20206284 SP - 2020.10.03.20206284 AU - Sam M. Lockhart AU - Harry Griffiths AU - Bogdan Petrisor AU - Ammara Usman AU - Julia Calvo-Latorre AU - Laura Heales AU - Vishakha Bansiya AU - Razeen Mahroof AU - Andrew Conway Morris Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/06/2020.10.03.20206284.abstract N2 - Objective Severe COVID-19 has been anecdotally associated with high insulin requirements. It has been proposed that this may be driven by a direct diabetogenic effect of the virus that is unique to SARS-CoV-2, but evidence to support this is limited. To explore this, we compared insulin requirements in patients with severe COVID-19 and non-COVID-19 viral pneumonitis.Research Design Retrospective cohort study of patients with severe COVID-19 admitted to our intensive care unit between March and June 2020. A historical control cohort of non-COVID-19 viral pneumonitis patients was identified from routinely collected audit data.Results Insulin requirements were similar in patients with COVID-19 and non-COVID-19 viral pneumonitis after adjustment for pre-existing diabetes and severity of respiratory failure.Conclusions In this single center study, we could not find evidence of a unique diabetogenic effect of COVID-19. We suggest that high insulin requirements in this disease relate to its propensity to cause severe respiratory failure in patients with pre-existing metabolic disease.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot registered as study was a retrospective analysis of routinely collected dataFunding StatementSL is supported by a National Institute of Health Research Academic Clinical Fellowship. ACM is supported by a Clinical Research Career Development Fellowship from the Wellcome Trust (WT 2055214/Z/16/Z)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As a retrospective analysis of anonymized, routinely collected data the requirement for ethical committee review and consent was waived by the National Health Service Health Research Authority, the evaluation was registered with the responsible healthcare organization (Cambridge University Hospitals NHS Foundation Trust).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFully anonymised data is available on request to the corresponding author. ER -